// App-Quantinova.ai

POS0639 (2021) : LONG-TERM EFFECTIVENESS OF THE RITUXIMAB HALF DOSE REGIMEN FOLLOWING A RESPONSE TO THE LICENSED DOSE IN RHEUMATOID ARTHRITIS

Researchers

Presenter

  • L. Garcia-Montoya

Principal Investigators

  • M. Y. Md Yusof

  • G. Eugnio

  • S. Das

  • E. Vital

  • P. Emery

Medical Centers

  • Leeds Biomedical Research Centre, NIHR, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Observational

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Roche

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved